2Mogensen CE, Schmitz A, Christensen CK. Comparative renal Pathophysiology relevant to IDDM and NIDDM patients. Diabetes Metabol Rev ,1988, (4) :453-483
3Coekcroft DW, Gault MH. Prediction of ereatinine clearance from serum creatinlne. Nephron 1976,16:31
4CAO Z, BONNET F, DAVIS B, et al. Additive hypotensive and anti-albuminuric effects of angiotensin-converting enzyme inhibition and angiotensin receptor antagonism in diabetic spontaneously hypertensive rats [J]. Clin Sci, 2001, 100(6) :591-599.
5KURIYAMA S, TOMONARI H, ABE A, et al. Beneficial effect of combination therapy with an angiotensin Ⅱ receptor antagonist and angiotensin-converting enzyme inhibitior on overt proteinuria in a patient with type 1 diabetic nephropathy [J]. Nephron, 2000, 86(4): 529-530.
6RUSSO D, PISANI A, BALLETTA MM, et al. Addictive antiproteinuric effect of convertingenzyme inhibitor and losartan in normotensive patients with IgA nephropathy [J]. Am J Kidney Dis,1999, 33 (5) :851-856.
7Gokce N, Keaney JF Jr, Hunter LM, et al. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function:a prospective study. Circulation, 2002, 105:1567-1572.
8Hink U, Li H, Mollnau H, et al. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res, 2001, 88:E14-E22.
9Ouvina SM, La Greca RD, Zanaro NL, et al. Endothelial dysfunction, nitric oxide and platelet activation in hypertensive and diabetic type Ⅱ patients. Thromb Res, 2001, 102:107-114.
